Israel-based Kitov Pharmaceuticals (TASE: KTOV) has announced more data from its successfully concluded Phase III trial for KIT-302.
The results revealed that favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in the study.
These data not only confirm the top line findings of the study – that KIT-302 was more efficacious at reducing hypertension than the widely used hypertension drug amlodipine besylate – but also reveal the benefits of using a combination drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze